Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Real Estate
  • Entertainment
  • Concealed Carry
  • Software
  • Non-profit
Washingtoner

Orlance, Inc. awarded RNA Vaccine Development Grant
Washingtoner/10263081

Trending...
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Spokane: Impacts For Final Stretch of Construction Season
SEATTLE, July 10, 2024 ~ Seattle-based biotech company, Orlance, Inc., has recently been granted a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The grant, worth $300,000 per year for two years, will be used to develop and optimize RNA vaccine formulations using Orlance's needle-free MACH-1™ platform.

The MACH-1 platform aims to enhance the safety, stability, and efficacy of RNA vaccines for infectious diseases such as influenza and Covid-19, as well as cancer immunotherapy applications. This technology represents a significant advancement in RNA vaccine delivery compared to traditional methods.

Unlike traditional lipid nanoparticle (LNP) RNA vaccine formulations that require ultra-cold storage and have been associated with rare adverse events like myocarditis, the MACH-1 platform utilizes dry, stable RNA-coated gold microparticles. These microparticles are propelled directly into the epidermis using a burst of pressurized gas. Once they penetrate the skin's outermost layer, they are taken up by immune cells that reside there.

More on Washingtoner
  • PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
  • Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
  • Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Spokane: Convicted Felon Arrested in Vancouver After Eluding SPD Officers

This needle-free and painless delivery system not only ensures better stability at ambient temperatures but also provides significant supply chain advantages in both developed and low-resource settings. Additionally, it can significantly improve patient comfort and compliance associated with discomfort and fear of needle-based injections.

The SBIR-funded project, titled "Gene Gun-delivered RNA vaccines," will be led by Orlance Principal Investigators Hannah Frizzell, PhD and Kenneth Bagley, PhD. The team aims to optimize RNA formulations for MACH-1 gene gun delivery that maximize loading, maintain functional integrity, and ensure stability and immunogenicity. They will also compare the effectiveness of MACH-1 delivered RNA vaccines against traditional LNP/RNA vaccines in inducing immune responses in preclinical models.

Preliminary studies have shown promising results with MACH-1 delivered RNA vaccines achieving comparable immunogenicity to LNP/RNA vaccines with significantly lower doses. Orlance co-founder and CEO, Kristyn Aalto, explains that while mRNA vaccines have shown great potential in recent years, there is still significant work to be done to improve their utility and global health impact.

More on Washingtoner
  • Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
  • AMR and UAS Take the Stage at WorldSkills Shanghai 2026
  • Volunteers Invited to Help Care for Tacoma's Parks and Natural Areas on Green Tacoma Day, October 10
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • JoCa's Echoes of Haworth Sells Out on Opening Night in Mexico City; Artist Heads to San Luis Potosí and Miami Art Week

The grant will enable Orlance to conduct crucial preclinical studies and pave the way for subsequent phases of development, ultimately leading to clinical trials. Aalto also mentions that Orlance already has a well-developed MACH-1 DNA vaccine candidate portfolio and offering both DNA and RNA vaccine options allows them to provide ideal solutions for specific indications.

Founded in 2016 as a spin-out from the University of Washington (UW), Orlance is focused on developing next-generation MACH-1 vaccines and cancer immunotherapies. With $13M in SBIR funding awarded to date, the company has made significant progress towards readiness for initial regulatory filings in 2024. They plan to initiate Phase I clinical trials for their lead infectious disease asset in 2025 and are actively partnering with other vaccine developers to develop MACH-1 vaccine and immunotherapy candidates across multiple indications.

Orlance's MACH-1 platform has the potential to revolutionize RNA vaccine delivery, making it safer, more stable, and more effective. With the support of NIH's SBIR grant, Orlance is one step closer to achieving their goal of improving global health through innovative genetic vaccines.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • Cummings Graduate Institute Celebrates New Doctor of Behavioral Health Graduates
  • Visit London Appoints The SEO Works for AI-First Search Strategy
  • Spokane: Parks & Recreation Secures Top Ranking for $4.6M in State Grant Match
  • City of Spokane to Install First 'Emergency Streets' Lane Closure After Weekend Fatal Crash
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo
  • Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
  • Tacoma: 'Preparing the Bid' Workshop on October 19
  • Tacoma: Street Operations Crew Scheduled to Conduct Snow and Ice Training October 12 – 14
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
  • Guberman to Business Owners, Implant Patients: Your ISO 9001,ISO 13485 AS9100,AI9100 Certificate Is Dead, and Nobody Knows What's Inside You
  • NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
  • Squaawke Releases a Hymn-Cycle Written for Intelligent Machines
  • Tickeron Launches New AI Trading Robots for Semi & Finance with Profit Factor 2.8 for Hedge Funds (JPM, BAC, NVDA, GOOG, AVGO, META, AMD)
  • Regional Magazines Shine at IRMA Awards
  • Spokane: Impacts For Final Stretch of Construction Season
_catLbl0 _catLbl1

Popular on Washingtoner

  • Continuous You Foundation Opens Applications For A 100-year Artist Grant - 153
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs - 146
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 144
  • DuoKey launches the World's First Agentic Crypto Agility Platform - 134
  • Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home - 111
  • Marti Reeder Ranked Among Washington State's Top Real Estate Brokers by RealTrends Verified - 103
  • Applicants Sought for Tacoma Public Library Board of Trustees
  • DAZN Review 2026: Streaming Price Worth It?
  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again
  • StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth

Similar on Washingtoner

  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
  • PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
  • Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
  • Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
  • Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute